The Next Sector Rotation Will Be To Biotechs

Loading...
Loading...

A sector rotation is common, particularly in times of market volatility. However, picking the timing and the right sector is always a concern for investors.

"There's always money coming out of something, going into something else," Joel Elconin, co-host of Benzinga's PreMarket Prep, said during Tuesday's daily show.

Dennis Dick, the show's co-host, jumped in and pointed that shares of Gilead Sciences, Inc. GILD "got killed" following its earnings release, and Biogen Inc BIIB has seen its shares "struggle for a while."

Dick continued that there is a major overhang is the U.S. presidential election and delved into what affect a potential Clinton presidency would have on the entire drug sector, specifically regarding any new drug pricing policies.

Related Link: Should Biotech Investors Take Hillary Clinton's Drug Pricing Plan Seriously?

"There is value here [in the biotech sector]," Dick said. "These companies make money."

As an example, Dick highlighted Pfizer Inc. PFE as a standout as the company is expected to see $53 billion in revenue this year and offers a healthy dividend yield of 3.75 percent. Meanwhile, Gilead's stock boasts a P/E multiple of approximately 8 to 9.

Dick continued that investors who buy biotech stocks at current levels will be "happy" in 5 years from now. He did however caution there might be "short-term pain" given the U.S. election.

Loading...
Loading...
Posted In: Analyst ColorBiotechPoliticsTop StoriesExclusivesTrading IdeasGeneralBenzinga PreMarket PrepBiotechBiotech StocksHillary Clinton
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...